
**RISK/BENEFIT ANALYSIS FOR THE USE AND APPROVAL OF:
THROMBOLYTIC, ANTIARRHYTHMIC, AND HYPOLIPIDEMIC AGENTS**

DEVELOPMENTS IN CARDIOVASCULAR MEDICINE

- Reiber, J.H.C., Serruys, P.W., Slager, C.J.: Quantitative coronary and left ventricular cineangiography. ISBN 0-89838-760-4.
- Fagard, R.H., Bekaert, I.E., eds.: Sports cardiology. ISBN 0-89838-782-5.
- Reiber, J.H.C., Serruys, P.W., eds.: State of the art in quantitative coronary arteriography. ISBN 0-89838-804-X.
- Roelandt, J., ed.: Color doppler flow imaging. ISBN 0-89838-806-6.
- van de Wall, E.E., ed.: Noninvasive imaging of cardiac metabolism. ISBN 0-89838-812-0.
- Liebman, J., Plonsey, R., Rudy, Y., eds.: Pediatric and fundamental electrocardiography. ISBN 0-89838-815-5.
- Higler, H., Hombach, V., eds.: Invasive cardiovascular therapy. ISBN 0-89838-818-X.
- Serruys, P.W., Meester, G.T., eds.: Coronary angioplasty: a controlled model for ischemia. ISBN 0-89838-819-8.
- Tooke, J.E., Smaje, L.H., eds.: Clinical investigation of the microcirculation. ISBN 0-89838-833-3.
- van Dam, Th., van Oosterom, A., eds.: Electrocardiographic body surface mapping. ISBN 0-89838-834-1.
- Spencer, M.P., ed.: Ultrasonic diagnosis of cerebrovascular disease. ISBN 0-89838-836-8.
- Legato, M.J., ed.: The stressed heart. ISBN 0-89838-849-X.
- Safar, M.E., ed.: Arterial and venous systems in essential hypertension. ISBN 0-89838-857-0.
- Roelandt, J., ed.: Digital techniques in echocardiography. ISBN 0-89838-861-9.
- Dhalla, N.S., Singal, P.K., Beamish, R.E., eds.: Pathophysiology of heart disease. ISBN 0-89838-864-3.
- Dhalla, N.S., Pierce, G.N., Beamish, R.E., eds.: Heart function and metabolism. ISBN 0-89838-865-1.
- Dhalla, N.S., Innes, I.R., Beamish, R.E., eds.: Myocardial ischemia. ISBN 0-89838-866-X.
- Beamish, R.E., Panagia, V., Dhalla, N.S., eds.: Pharmacological aspects of heart disease. ISBN 0-89838-867-8.
- Ter Keurs, H.E.D.J., Tyberg, J.V., eds.: Mechanics of the circulation. ISBN 0-89838-870-8.
- Sideman, S., Beyar, R., eds.: Activation metabolism and perfusion of the heart. ISBN 0-89838-871-6.
- Aliot, E., Lazzara, R., eds.: Ventricular tachycardias. ISBN 0-89838-881-3.
- Schneeweiss, A., Schettler, G.: Cardiovascular drug therapy in the elderly. ISBN 0-89838-883-X.
- Chapman, J.V., Sgalambro, A., eds.: Basic concepts in doppler echocardiography. ISBN 0-89838-888-0.
- Chien, S., Dormandy, J., Ernst, E., Matrai, A., eds.: Clinical hemorheology. ISBN 0-89838-807-4.
- Morganroth, J., Moore, E. Neil, eds.: Congestive heart failure. ISBN 0-89838-955-0.
- Heintzen, P.H., Bursch, J.H., eds.: Progress in digital angiocardiology. ISBN 0-89838-965-8.
- Scheinman, M., ed.: Catheter ablation of cardiac arrhythmias. ISBN 0-89838-967-4.
- Spaan, J.A.E., Brusckhe, A.V.G., Gittenberger, A.C., eds.: Coronary circulation. ISBN 0-89838-978-X.
- Bayes de Luna, A., ed.: Therapeutics in cardiology. ISBN 0-89838-981-X.
- Mirvis, D.M., ed.: Body Surface Electrocardiographic Mapping. ISBN 0-89838-983-6.
- Visser, C., Kan, G., Meltzer, R., eds.: Echocardiography in coronary artery disease. ISBN 0-89838-979-8.
- Singal, P.K., ed.: Oxygen Radicals in the Pathophysiology of Heart Disease. ISBN 0-89838-375-7.
- Iwata, H., Lombardini, J.B., Segawa, T., eds.: Taurine and the heart. ISBN 0-89838-983-6.
- Mirvis, D.M., ed.: Body surface electrocardiographic mapping. ISBN 0-89838-983-6.
- Morganroth, J., Moore, E.N., eds.: Silent myocardial ischemia. ISBN 0-89838-380-3.
- Morganroth, J., Moore, E.N., eds.: Risk/benefit analysis for the use and approval of: thrombolytic, antiarrhythmic, and hypolipidemic agents. ISBN 0-7923-0294-X.

**RISK/BENEFIT ANALYSIS FOR THE USE AND
APPROVAL OF THROMBOLYTIC, ANTIARRHYTHMIC,
AND HYPOLIPIDEMIC AGENTS**

PROCEEDINGS OF THE NINTH ANNUAL SYMPOSIUM ON NEW
DRUGS & DEVICES, OCTOBER 27 & 28, 1988

Edited by

JOEL MORGANROTH
LIKOFF CARDIOVASCULAR INSTITUTE
OF HAHNEMANN MEDICAL COLLEGE AND HOSPITAL

and

E. NEIL MOORE
SCHOOL OF VETERINARY MEDICINE
UNIVERSITY OF PENNSYLVANIA



KLUWER ACADEMIC PUBLISHERS
BOSTON DORDRECHT LONDON

Distributors for North America:
Kluwer Academic Publishers
101 Philip Drive
Assinippi Park
Norwell, Massachusetts 02061 USA

Distributors for all other countries:
Kluwer Academic Publishers Group
Distribution Centre
Post Office Box 322
3300 AH Dordrecht, THE NETHERLANDS

Library of Congress Cataloging-in-Publication Data
Symposium on New Drugs and Devices (9th : 1988 :
Philadelphia, Pa.)
Risk/benefit analysis for the use and approval of
thrombolytic, antiarrhythmic, and hypolipidemic agents.

(Developments in cardiovascular medicine ; 100)

Includes index.

1. Fibrinolytic agents—Effectiveness—Congresses.
 2. Myocardial depressants—Effectiveness—Congresses.
 3. Antilipemic agents—Effectiveness—Congresses.
 4. Risk assessment—Congresses. I. Morganroth, Joel.
II. Moore, E. Neil III. Title. IV. Series: Develop-
ments in cardiovascular medicine ; v. 100.
- [DNLM: 1. Anti-Arrhythmia Agents—therapeutic use—
congresses. 2. Antilipemic Agents—therapeutic use—
congresses. 3. Fibrinolytic Agents—therapeutic use—
congresses. W1 DE997VME v.100 / QA 190 S9895r]
RC685.C6S94 1988 615'.71 89-11044

ISBN-13: 978-1-4612-8888-6

e-ISBN-13: 978-1-4613-1605-3

DOI: 10.1007/978-1-4613-1605-3

Copyright © 1989 by Kluwer Academic Publishers

Softcover reprint of the hardcover 1st edition 1989

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, mechanical, photocopying, recording, or otherwise, without the prior written permission of the publisher, Kluwer Academic Publishers, 101 Philip Drive, Assinippi Park, Norwell, Massachusetts 02061.

CONTENTS

Faculty Preface

xii
ix

I. THROMBOLYTIC AGENTS: CLINICAL TRIALS ISSUES

1. Measurement of infarct size: effect of reperfusion with arterial blood
Robert B. Jennings, Keith A. Reimer 3
2. Pitfalls in the design and evaluation of clinical trials of intravenously administered cardiovascular drugs
Milton Packer 15
3. The relative benefit and risks of intravenous streptokinase and tissue plasminogen activator in acute myocardial infarction
Allan M. Ross 23
4. New agents and new insights for thrombolytic therapy in acute myocardial infarction: focus on anistreplase, urokinase, and prourokinase
Jeffrey L. Anderson 29
5. Myocardial reperfusion: Role of adjunctive agents to improve reperfusion and prevent reperfusion injury
B. Pitt, B. Lucchesi 47

Panel Discussion 59

II. THROMBOLYTIC AGENTS: ADJUNCTIVE ISSUES

6. Interactions between thrombolysis and sudden cardiac death
E. Neil Moore, Joseph F. Spear 93
7. What are the overall strategies for post-thrombolytic care that include use of angioplasty?
Carl Pepine 99

8. Thrombolytic agents: biologic properties and issues regarding products derived by recombinant DNA technology Gerle Murano	109
Panel Discussion	117
III. RISK VS. BENEFIT FOR ANTIARRHYTHMIC DRUGS	143
9. What do new anti-arrhythmic agents have to show to establish a favorable risk versus benefit ratio? Robert Temple	145
10. What do new cardiovascular agents (e.g. antiarrhythmic drugs) have to show to establish a favorable risk versus benefit ratio to obtain approvability? - clinical viewpoint Curt D. Furberg	153
11. Is it practical to develop a class III antiarrhythmic agent? H.P.K. Agersborg, J. Latts	157
Panel Discussion	167
IV. HYPOLIPIDEMIC AGENTS: CLINICAL & REGULATORY ISSUES	
12. What are the recommendations to the medical community to institute hypolipidemic therapy? Joel Morganroth	201
13. What are the comparative risks versus benefits for bile acid sequestrants, HMG CO-A reductase inhibitors, nicotinic acid, probucol, and fibric acid derivatives? Robert I. Levy, Conrad Blum	215
14. What levels of cholesterol should be studied and what should be the study designs? Gloria Troendle	225

vii

15. Should a change in the atherosclerotic process be required for approval of new hypolipidemic agents? Curt Furberg, Robert Byington, Mark Espeland	233
16. How and when should long-term safety data be obtained for hypolipidemic agents? L. Ross Pierce	241
17. What is required to gain approval of lipid altering drugs? Solomen Sobel	249
Panel Discussion	253
PARTICIPANT LIST	279

PREFACE

The Symposium on New Drugs provides a forum for academic investigators, research and development personnel from the pharmaceutical industry and members of the Food and Drug Administration to discuss important clinical research issues. The Ninth Annual Symposium on New Drugs addressed the problem of determining the risk versus benefit for use of three important classes of cardiovascular agents: thrombolytic, antiarrhythmic, and hypolipidemic agents.

The use of thrombolytic agents has become one of the major advances in clinical intensive cardiologic care in the 1980s. While the lysis of clot(s) obstructing a major coronary artery should reverse or prevent the damage of acute myocardial ischemia and infarction, one must carefully consider the potential risks of such agents in regards to their potential benefits. The time when a thrombolytic agent should be administered to maximize benefit as well as how one defines a dose response relationship using intravenous critical care medicines were discussed as important clinical trial issues. The benefit versus risk data on currently available thrombolytic agents was reviewed and the potential roles for adjunctive agents addressed. Overall strategies regarding post-

thrombolytic care and relationships to sudden cardiac death were also detailed. The panel discussion sections provided a comprehensive view of the current thinking of the various participating groups in this Symposium.

Sudden cardiac death remains the number one cause of mortality in western industrialized societies. The potential for antiarrhythmic drug therapy to reverse this epidemic still has not been established; in fact, new antiarrhythmic drugs with better benefit versus risk ratios may be necessary to determine this endpoint. The viewpoints of the Food and Drug Administration as well as clinical academic investigators were reviewed. In addition, the pharmaceutical industry's concern regarding the practicality of developing new antiarrhythmic agents under current guidelines was emphasized.

The potential for preventing or reversing the atherosclerotic process and coronary events by reducing elevated atherogenic lipoproteins has provided an exciting new area for preventive therapy. New recommendations to the medical community regarding criteria for institution of hypolipidemic therapy may substantially influence the nature of clinical trials in this field. Comparative risks versus benefits for

the currently available hypolipidemic agents as well as design issues such as defining endpoints in clinical trials were detailed. Current guidelines to obtain regulatory approval for new lipid lowering agents were also discussed.

We believe the positions presented in the various manuscripts as well as the principles illucidated during the panel discussions should provide the reader a current state-of-the-art understanding as well as clues for future directions in these important cardiovascular therapeutic classes.

Joel Morganroth, M.D.
E. Neil Moore, DVM, Ph.D.

Philadelphia, Pennsylvania, U.S.A.

SYMPOSIUM ON NEW DRUGS AND DEVICES

OCTOBER 27-28, 1988

FACULTY

H.P.K. Agersborg, Jr., Ph.D.
President
Wyeth-Ayerst Research
P.O. Box 8299
Philadelphia, Pennsylvania 19101
(215) 971-5820

Jeffrey L. Anderson, M.D.
Cardiology Division
LDS Hospital
Eighth Avenue and C Street
Salt Lake City, Utah 84143
(801) 321-5300

James M. Bilstad, M.D.
Director, Office of Drug Evaluation II
Center for Drug Evaluation & Research
Food and Drug Administration
Room 13-B-28
HFD-500
5600 Fishers Lane
Rockville, Maryland 20857
(301) 443-2544

W. Virgil Brown, M.D.
President & CEO
Medlantic Research Foundation
George Hyman Memorial Research Building
108 Irving Street, N.W.
Washington, DC 20010
(202) 877-3700

Curt D. Furberg, M.D.
Professor of Medicine
Bowman Gray School of Medicine
300 S. Hawthorne Road
Winston-Salem, North Carolina 27103
(919) 748-3730

Frank E. Harrell, Jr., Ph.D.
Associate Professor of Biostatistics
Division of Biometry
Box 3363
Duke University Medical Center
Durham, North Carolina 27710
(919) 681-2406

Donald B. Hunninghake, M.D.
Professor of Medicine and Pharmacology
Heart Disease Prevention Clinic
401 East River Road
Box 192
University of Minnesota Hospitals & Clinics
Minneapolis, Minnesota 55455
(612) 625-3982

Robert B. Jennings, M.D.
James B. Duke Professor & Chairman
Department of Pathology
Duke University Medical Center
Box 3712
Durham, North Carolina 27710
(919) 684-3528

Peter R. Kowey, M.D.
Professor of Medicine
Division of Cardiology
The Medical College of Pennsylvania
3300 Henry Avenue
Philadelphia, Pennsylvania 19129
(215) 842-7455

Robert I. Levy, M.D.
President
Sandoz Research Institute
Route 10
East Hanover, New Jersey 07936
(201) 503-8120

Raymond J. Lipicky, M.D.
Director
Division of Cardiorenal Drug Products
Food and Drug Administration
Room 16-B-45
5600 Fishers Lane
Rockville, Maryland 20857
(301) 443-4730

Benedict R. Lucchesi, Ph.D., M.D.
Professor of Pharmacology
The University of Michigan Medical School
Medical Science Building M6322
Ann Arbor, Michigan 48109
(313) 747-3134

Franz H. Messerli, M.D.
Associate Head, Division of Hypertension
Ochsner Clinic
1514 Jefferson Highway
New Orleans, Louisiana 70121
(504) 838-4077

E. Neil Moore, DVM, Ph.D.
Professor of Physiology in Medicine
University of Pennsylvania
School of Veterinary Medicine
3800 Spruce Street
Philadelphia, Pennsylvania 19104
(215) 898-8897

Joel Morganroth, M.D.
Director of Cardiac Research & Development
The Graduate Hospital
Professor of Medicine & Pharmacology
Hahnemann University
The Graduate Hospital
One Graduate Plaza
Philadelphia, Pennsylvania 19146
(215) 790-8010

Gene Murano, M.D.
Research Physiologist
Food and Drug Administration
Building 29
Room 324
8800 Rockville Pike
Bethesda, Maryland 20205
(301) 496-0455

Milton Packer, M.D.
Professor of Medicine
Division of Cardiology
Mt. Sinai Medical Center
100th Street and Fifth Avenue
New York, New York 10029
(212) 241-4029

Carl J. Pepine, M.D.
Professor of Medicine
Department of Medicine (Cardiology)
University of Florida
Gainesville, Florida 32610
(904) 374-6052

L. Ross Pierce, M.D.
Supervisory Medical Officer
Division of Metabolism and
Endocrine Drug Products
Food and Drug Administration
HFD-510
Room 14-B-04
5600 Fishers Lane
Rockville, Maryland 20857
(301) 443-3490

Bertram Pitt, M.D.
Professor of Internal Medicine
Director, Division of Cardiology
University Hospitals
1500 East Medical Center Drive
3910 Taubman
Ann Arbor, MI 48109-0366
313-936-5255

Allan M. Ross, M.D.
Professor of Medicine
Director, Division of Cardiology
George Washington University
2150 Pennsylvania Avenue, N.W.
Washington, DC 20037
(202) 994-3777

Solomon Sobel, M.D.
Director, Division of Metabolism and
Endocrine Drug Products
Food and Drug Administration
HFD-510
Room 14-B-04
5600 Fishers Lane
Rockville, Maryland 20857
(301) 443-3490

Robert Temple, M.D.
Director, Office of Drug Evaluation I
Food and Drug Administration
HFD-100
Room 14-B-45
5600 Fishers Lane
Rockville, Maryland 20857
(301) 443-4330

Gloria Troendle, M.D.
Deputy Director
Division of Metabolism and
Endocrine Drug Products
Food and Drug Administration
HFD-510
Room 14-B-04
5600 Fishers Lane
Rockville, Maryland 20857
(301) 443-3490